Upstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2

UPB-101 safety, tolerability, and PK/PD results support advancing to Phase 2 in Q1 2024 Findings reveal potency and receptor occupancy supporting Phase 2 dosing regimens at 12-week and 24-week intervals WALTHAM, Mass. – October 24, 2023 – Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced positive interim results in […] The post Upstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2 appeared first on Upstream Bio .